Zynex Announces 4th Quarter and Year-End Revenue Guidance Update

News provided by

Jan 08, 2018, 09:04 ET

LONE TREE, Colo., Jan. 8, 2018 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced an update to its previously announced revenue estimate for the fourth quarter.

Zynex updates its Fourth Quarter Revenue Estimate to between $7.5 and $8.0 million. The previous estimate, established in November 2017 was between $7.0 and $7.5 million. The revenue in the fourth quarter of 2016 was $2.9 million and the most recent third quarter of 2017 was $6.8 million. The full year 2017 revenue is now estimated to come in between $22.8 and $23.3 million compared to $13.3 million in 2016. The company expects to file its full year and fourth quarter financials on or before March 31, 2018.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.

Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
[email protected]

SOURCE Zynex